ClinicalTrials.gg
WithdrawnNCT03301766Updated Jun 29, 2023

Adjunctive 5% Lidocaine Patches for Acute Non-radicular Low Back Pain in Emergency Department Patients

A Phase 4 interventional study of lidocaine 5% patch and standard therapy in Low Back Pain, sponsored by Cook County Health. Withdrawn at 1 site in United States. Open to participants aged 24 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-06-29.

Sponsored by Cook County Health · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Delay for subject recruitment and then not feasible with COVID\>

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2017, registered Sep 2017).
Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
24 Years to 64 Years
Sex
All
01

Study summary

This study will evaluate the addition of lidocaine % transdermal patches to standard therapy in the treatment of acute non-radicular low back pain in patients discharged from the Emergency Department. In addition to standard therapy, half of the participants will receive medicated patches while the other half will receive non-medicated patches.

Read the detailed description

Low back pain is a common emergency department (ED) chief complaint. Multiple therapies have been evaluated in the treatment of ED patients with low back pain including acetaminophen, NSAIDS, opioids, steroids, and muscle relaxants.

Lidocaine is a local anesthetic that can be administered by various routes. It is used in a transdermal patch for the treatment of pain. It is commonly used for focal causes of pain, including low back pain. The addition of lidocaine 5% patches to standard low back pain therapy has not been rigorously evaluated, although it is frequently used.

02

Conditions studied

  • Low Back Pain

Browse trials for

Keywords

  • lidocaine
03

In context

Low Back Pain

2,922 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.

Browse Low Back Pain studies →

Lead sponsor

Cook County Health is the lead sponsor of 28 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pain originating between the lower border of the scapulae and the upper gluteal folds
  • treating ED physician plan for discharge of the patient

Exclusion criteria

Exclusion Criteria:

  • radicular pain defined as pain radiating below the gluteal folds
  • direct trauma to the back within previous month
  • pain of greater than 2 weeks duration or greater than 1 LBP episode per month in the past 3 months
  • patient being pregnant or lactating; no access to phone or ability to participate in follow-up phone calls
  • known allergy to lidocaine or skin breakdown over site of pain
  • treating physician plan for opioid prescription (tramadol, codeine, hydrocodone)
  • personal history of , fever (temperature greater than 37.9ºC), or previous spinal surgery
  • patients who are detainees
  • previous enrollment in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Lidocaine 5% patch

    Patients will receive a 7 day supply (21 patches) of lidocaine 5% patches upon discharge from the emergency department in addition to "standard therapy" at the discretion of the treating emergency department physician.

    Drug: lidocaine 5% patch · Drug: standard therapy

  • Active comparator
    Non-medicated patch

    Patients will receive a 7 day supply (21 patches) of non-medicated patches upon discharge from the emergency department in addition to "standard therapy" at the discretion of the treating emergency department physician.

    Drug: standard therapy · Drug: Non-medicated patch

Interventions

  • transdermal patch

  • Drugstandard therapy

    Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)

  • DrugNon-medicated patch

    non-medicated patch

06

What researchers measure

Primary outcomes

  1. Numerical Pain Rating Scale (NRS)

    Patient description of pain on a scale of 0-10

    Time frame: 1 week

Secondary outcomes

  1. Roland-Morris-24 back pain disability scale

    24 point back pain disability scale

    Time frame: 1 week and 1 month

  2. Numerical Pain Rating Scale (NRS)

    Patient description of pain on a scale of 0-10

    Time frame: 1 month

Other outcomes

  1. Repeat visits

    Repeat visits to an emergency department

    Time frame: 1 week and 1 month

07

Study locations

1 site
  • John H Stroger Jr Hospital of Cook County
    Chicago, Illinois 60612, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in May 2023, 74 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2017
First posted
Oct 4, 2017
StartActual
Mar 10, 2017
Primary completionActual
May 22, 2023
CompletionActual
May 22, 2023
Last update
Jun 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03301766
Lead sponsor
Cook County Health
Responsible party
Neeraj Chhabra (Attending Physician, Department of Emergency Medicine, Principal Investigator, Cook County Health) — Principal investigator
First posted
Oct 4, 2017
Start date
Mar 10, 2017
Primary completion
May 22, 2023
Completion
May 22, 2023
Last update
Jun 29, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion